SB-681323 Tablets
( DrugBank: - / KEGG DRUG: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 8 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
Showing 1 to 8 of 8 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002219-26-NO (EUCTR) | 05/09/200620060905 | 18/07/200520050718 | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | Rheumatoid arthritis (RA) | Product Name: SB-681323 Tablets Product Code: SB-681323 | GlaxoSmithKline R&D Ltd | NULL | Not Recruiting | Female: yes Male: yes | 82 | Phase 2 | Hungary;Spain;Denmark;Germany;Norway;Italy;United Kingdom;Sweden | ||
| 2 | EUCTR2005-002219-26-GB (EUCTR) | 20/03/200620060320 | 13/01/200620060113 | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | Rheumatoid arthritis (RA) | Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: S ... | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 82 | Phase 2 | Hungary;Spain;Denmark;Germany;Norway;Italy;United Kingdom;Sweden | ||
| 3 | EUCTR2005-002219-26-DE (EUCTR) | 09/11/200520051109 | 20/07/200520050720 | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | Rheumatoid arthritis (RA) | Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: S ... | GlaxoSmithKline R&D Ltd | NULL | Not Recruiting | Female: yes Male: yes | 82 | Hungary;United Kingdom;Germany;Norway;Spain;Italy;Sweden | |||
| 4 | EUCTR2005-002219-26-ES (EUCTR) | 21/09/200520050921 | 10/10/200520051010 | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | Rheumatoid arthritis (RA) | Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: S ... | GlaxoSmithKline S.A. | NULL | Not Recruiting | Female: yes Male: yes | 82 | Phase 2 | Hungary;Spain;Denmark;Germany;Norway;Italy;United Kingdom;Sweden | ||
| 5 | EUCTR2004-005115-29-DE (EUCTR) | 14/09/200520050914 | 16/05/200620060516 | A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with acti ... | A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with acti ... | Rheumatoid arthritis | Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: Overencapsulated Prednisolone Tablets INN or Proposed INN: Prednisolone Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: S ... | GlaxoSmithKline R&D Ltd | NULL | Not Recruiting | Female: yes Male: yes | 77 | United Kingdom;Germany | |||
| 6 | EUCTR2005-002219-26-SE (EUCTR) | 08/09/200520050908 | 14/07/200520050714 | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | Rheumatoid arthritis (RA) | Product Name: SB-681323 Tablets Product Code: SB-681323 | GlaxoSmithKline R&D Ltd | NULL | Not Recruiting | Female: yes Male: yes | 82 | Hungary;United Kingdom;Germany;Norway;Spain;Italy;Sweden | |||
| 7 | EUCTR2005-002219-26-DK (EUCTR) | 23/08/200520050823 | 09/08/200520050809 | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA) A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolera ... | Rheumatoid arthritis (RA) | Product Name: SB-681323 Tablets Product Code: SB-681323 | GlaxoSmithKline R&D Ltd | NULL | Not Recruiting | Female: yes Male: yes | 82 | Phase 2 | Hungary;Spain;Denmark;Germany;Norway;Italy;United Kingdom;Sweden | ||
| 8 | EUCTR2004-005115-29-GB (EUCTR) | 24/06/200520050624 | 27/05/200520050527 | A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with acti ... | A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with acti ... | Rheumatoid arthritis | Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: SB-681323 Trade Name: Prednisolone Tablets BP Product Name: Overencapsulated Prednisolone Tablets INN or Proposed INN: Prednisolone Product Name: SB-681323 Tablets Product Code: SB-681323 Product Name: SB-681323 Tablets Product Code: S ... | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 2 | Germany;United Kingdom |